Dendreon Corp (NASDAQ:DNDN)
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
bIlluminati
(31.15)
Submitted: 5/13/2013 3:59:57 PM :
Start Price:
$3.81
DNDN Score:
-2.21
No earnings.
Recs
Orbantibor
(< 20)
Submitted: 4/28/2013 2:30:00 AM :
Start Price:
$3.98
DNDN Score:
-2.31
The new tv ads turnus sales up, which crucial
Recs
BACnumber1
(< 20)
Submitted: 3/8/2013 11:21:10 AM :
Start Price:
$5.99
DNDN Score:
+41.00
Now look. I love most pharma companies. However there is no cure for cancer and very little progress has been made for a cure in the past many years. I am way more bullish on stocks like ARNA and NVO, as diabetes is an epidemic which IS on the other hand gaining momentum....
Recs
NHWeston102
(74.20)
Submitted: 2/15/2013 1:41:06 PM :
Start Price:
$6.19
DNDN Score:
+45.17
Peaked and headed down.
Recs
wayouy
(< 20)
Submitted: 2/1/2013 3:51:04 PM :
Start Price:
$5.97
DNDN Score:
-43.57
price per dose will fall in line with market pricing and sales will increase leading to profitability, plus huge short position makes it worth the risk at this price pint
Recs
TheAmerican7676
(< 20)
Submitted: 1/17/2013 7:59:32 PM :
Start Price:
$6.50
DNDN Score:
-51.37
Biotech pipeline 1 billion market cap growth and pipeline of drugs for clinical trials
Recs
Frimax32
(< 20)
Submitted: 1/4/2013 12:09:59 PM :
Start Price:
$6.10
DNDN Score:
-48.76
I understand they bottomed out and FDA has become tolerant
Recs
Investstack
(< 20)
Submitted: 11/16/2012 11:06:08 AM :
Start Price:
$3.98
DNDN Score:
-23.86
The imunization technology goes well beyond prostate cancer and can be applied to many cancers and has been patented. Expansion to Europe and Asia will help but ongoing tests of use of Provenge for earlier stage prostate and other cancers offer a potentially new form of cure with little to no side effects. Could be a buyout but the technology has a high value once management comes up with a plan to expand use.
Recs
rrdas
(< 20)
Submitted: 10/31/2012 9:33:03 PM :
Start Price:
$3.82
DNDN Score:
-13.74
Time to buy DNDN. When everyone is scared and its time to be greedy. It will run like PCYC.
Recs
pavlos1971
(99.63)
Submitted: 7/31/2012 12:36:19 PM :
Start Price:
$6.34
DNDN Score:
-59.04
RL@4.89. open@4.68
Recs
zzlangerhans
(99.78)
Submitted: 7/10/2012 7:11:41 PM :
Start Price:
$6.69
DNDN Score:
-63.55
Talk about playing with fire. Every time Dendreon dips, I wonder if there's another upward run left or if this is the swirl. I've been sucked into as many swirls as anyone, but on CAPS I make my parameters and stick to my guns. The burn is still obscene, the debt is atrocious, but there's 500M in cash as of the end of Q2 which gives the company at least a year to pull rabbits out of their hat. The only question is, will the rabbit pop out at a share price of 6 or 2?
Recs
islandsunsetter
(< 20)
Submitted: 6/14/2012 1:47:56 AM :
Start Price:
$7.30
DNDN Score:
-71.27
Nice strong bounce on lots of good rumors.
Recs
FWWright
(< 20)
Submitted: 6/13/2012 4:44:48 PM :
Start Price:
$7.30
DNDN Score:
-71.27
I think Provenge will be part of a multiple treatment path for a subset of Prostate cancer patients and thus the product will survive. Also, DNDN has an FDA approved facility that could be used for other personalized-vaccines. Finally, the stock is way oversold and should benefit from some short-covering.
Recs
Fishboy1970
(< 20)
Submitted: 6/10/2012 8:15:33 PM :
Start Price:
$6.36
DNDN Score:
-61.56
Zytiga will not get through the FDA and be approved in the pre-chemo setting. ASCO presentation says Provenge goes first!
Recs
rparnell76
(< 20)
Submitted: 5/3/2012 12:30:03 AM :
Start Price:
$11.75
DNDN Score:
-84.62
I think they will do well now that they are on the move up. We will see.
Recs
sunvestor7
(< 20)
Submitted: 3/23/2012 10:46:16 AM :
Start Price:
$9.92
DNDN Score:
-79.50
Unique therapy.
Recs
rightminded
(< 20)
Submitted: 3/2/2012 6:23:25 AM :
Start Price:
$11.51
DNDN Score:
-86.24
StockConsultant - 18
Recs
Recs
portefeuille
(99.77)
Submitted: 12/23/2011 5:06:06 AM :
Start Price:
$7.49
DNDN Score:
-78.59
There are currently 1100 DNDN shares in my "fund" with break-even of around 6.81 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
Azurik
(< 20)
Submitted: 11/2/2011 12:35:25 PM :
Start Price:
$10.22
DNDN Score:
-95.05
DNDN will outperform as Provenge becomes the blockbuster it should have been, once reimbursement program is clear to doctors.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 345 : 1 2 3 4 5 6 7 8 9 10 Next »